Literature DB >> 20600793

Anaplasma phagocytophilum APH_0032 is expressed late during infection and localizes to the pathogen-occupied vacuolar membrane.

Bernice Huang1, Matthew J Troese, Dale Howe, Shaojing Ye, Jonathan T Sims, Robert A Heinzen, Dori L Borjesson, Jason A Carlyon.   

Abstract

Anaplasma phagocytophilum infects neutrophils and myeloid, endothelial, and tick cell lines to reside within a host cell-derived vacuole that is indispensible for its survival. Here, we identify APH_0032 as an Anaplasma-derived protein that associates with the A. phagocytophilum-occupied vacuolar membrane (AVM). APH_0032 is a 66.1 kDa acidic protein that electrophoretically migrates with an apparent molecular weight of 130 kDa. It contains a predicted transmembrane domain and tandemly arranged direct repeats that comprise 46% of the protein. APH_0032 is undetectable on Anaplasma organisms bound to the surfaces of HL-60 cells, but is detected on the AVM and surfaces of intravacuolar bacteria beginning 24 h post-infection. APH_0032 localizes to the AVM in HL-60, THP-1, HMEC-1, and ISE6 cells. APH_0032, along with APH_1387, which encodes a confirmed AVM protein, is transcribed during A. phagocytophilum infection of tick salivary glands and murine neutrophils. APH_0032 localizes to the AVM in neutrophils recovered from infected mice. The Legionella pneumophila Dot/IcM type IV secretion system (T4SS) can heterologously secrete a CyaA-tagged version of the A. phagocytophilum VirB/D T4SS effector, AnkA, but fails to secrete CyaA-tagged APH_0032 or APH_1387. These data confirm APH_0032 as an Anaplasma-derived AVM protein and hint that neither it nor APH_1387 are T4SS effectors. Copyright 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20600793      PMCID: PMC2919654          DOI: 10.1016/j.micpath.2010.06.009

Source DB:  PubMed          Journal:  Microb Pathog        ISSN: 0882-4010            Impact factor:   3.848


  54 in total

1.  A secondary structure motif predictive of protein localization to the chlamydial inclusion membrane.

Authors:  J P Bannantine; R S Griffiths; W Viratyosin; W J Brown; D D Rockey
Journal:  Cell Microbiol       Date:  2000-02       Impact factor: 3.715

2.  Anaplasma phagocytophilum APH_1387 is expressed throughout bacterial intracellular development and localizes to the pathogen-occupied vacuolar membrane.

Authors:  Bernice Huang; Matthew J Troese; Shaojing Ye; Jonathan T Sims; Nathan L Galloway; Dori L Borjesson; Jason A Carlyon
Journal:  Infect Immun       Date:  2010-03-08       Impact factor: 3.441

3.  Positive charge is an important feature of the C-terminal transport signal of the VirB/D4-translocated proteins of Agrobacterium.

Authors:  Annette C Vergunst; Miranda C M van Lier; Amke den Dulk-Ras; Thomas A Grosse Stüve; Anette Ouwehand; Paul J J Hooykaas
Journal:  Proc Natl Acad Sci U S A       Date:  2005-01-11       Impact factor: 11.205

4.  Effects of Anaplasma phagocytophilum on host cell ferritin mRNA and protein levels.

Authors:  Jason A Carlyon; Dara Ryan; Kristina Archer; Erol Fikrig
Journal:  Infect Immun       Date:  2005-11       Impact factor: 3.441

5.  Identification of a granulocytotropic Ehrlichia species as the etiologic agent of human disease.

Authors:  S M Chen; J S Dumler; J S Bakken; D H Walker
Journal:  J Clin Microbiol       Date:  1994-03       Impact factor: 5.948

6.  Mass spectrometric analysis of Ehrlichia chaffeensis tandem repeat proteins reveals evidence of phosphorylation and absence of glycosylation.

Authors:  Abdul Wakeel; Xiaofeng Zhang; Jere W McBride
Journal:  PLoS One       Date:  2010-03-04       Impact factor: 3.240

7.  A variable-length PCR target protein of Ehrlichia chaffeensis contains major species-specific antibody epitopes in acidic serine-rich tandem repeats.

Authors:  Tian Luo; Xiaofeng Zhang; Abdul Wakeel; Vsevolod L Popov; Jere W McBride
Journal:  Infect Immun       Date:  2008-01-22       Impact factor: 3.441

8.  Protein antigens of Chlamydia psittaci present in infected cells but not detected in the infectious elementary body.

Authors:  D D Rockey; J L Rosquist
Journal:  Infect Immun       Date:  1994-01       Impact factor: 3.441

9.  Anaplasma phagocytophilum AnkA secreted by type IV secretion system is tyrosine phosphorylated by Abl-1 to facilitate infection.

Authors:  Mingqun Lin; Amke den Dulk-Ras; Paul J J Hooykaas; Yasuko Rikihisa
Journal:  Cell Microbiol       Date:  2007-06-24       Impact factor: 3.715

10.  Comparative genomics of emerging human ehrlichiosis agents.

Authors:  Julie C Dunning Hotopp; Mingqun Lin; Ramana Madupu; Jonathan Crabtree; Samuel V Angiuoli; Jonathan A Eisen; Jonathan Eisen; Rekha Seshadri; Qinghu Ren; Martin Wu; Teresa R Utterback; Shannon Smith; Matthew Lewis; Hoda Khouri; Chunbin Zhang; Hua Niu; Quan Lin; Norio Ohashi; Ning Zhi; William Nelson; Lauren M Brinkac; Robert J Dodson; M J Rosovitz; Jaideep Sundaram; Sean C Daugherty; Tanja Davidsen; Anthony S Durkin; Michelle Gwinn; Daniel H Haft; Jeremy D Selengut; Steven A Sullivan; Nikhat Zafar; Liwei Zhou; Faiza Benahmed; Heather Forberger; Rebecca Halpin; Stephanie Mulligan; Jeffrey Robinson; Owen White; Yasuko Rikihisa; Hervé Tettelin
Journal:  PLoS Genet       Date:  2006-02-17       Impact factor: 5.917

View more
  33 in total

1.  The Coxiella burnetii cryptic plasmid is enriched in genes encoding type IV secretion system substrates.

Authors:  Daniel E Voth; Paul A Beare; Dale Howe; Uma M Sharma; Georgios Samoilis; Diane C Cockrell; Anders Omsland; Robert A Heinzen
Journal:  J Bacteriol       Date:  2011-01-07       Impact factor: 3.490

Review 2.  Mechanisms of obligatory intracellular infection with Anaplasma phagocytophilum.

Authors:  Yasuko Rikihisa
Journal:  Clin Microbiol Rev       Date:  2011-07       Impact factor: 26.132

Review 3.  The role of CD8 T lymphocytes in rickettsial infections.

Authors:  David H Walker; J Stephen Dumler
Journal:  Semin Immunopathol       Date:  2015-04-01       Impact factor: 9.623

4.  Subversion of NPC1 pathway of cholesterol transport by Anaplasma phagocytophilum.

Authors:  Qingming Xiong; Yasuko Rikihisa
Journal:  Cell Microbiol       Date:  2012-02-08       Impact factor: 3.715

Review 5.  Anaplasma phagocytophilum: deceptively simple or simply deceptive?

Authors:  Maiara S Severo; Kimberly D Stephens; Michail Kotsyfakis; Joao Hf Pedra
Journal:  Future Microbiol       Date:  2012-06       Impact factor: 3.165

6.  Anaplasma phagocytophilum increases the levels of histone modifying enzymes to inhibit cell apoptosis and facilitate pathogen infection in the tick vector Ixodes scapularis.

Authors:  Alejandro Cabezas-Cruz; Pilar Alberdi; Nieves Ayllón; James J Valdés; Raymond Pierce; Margarita Villar; José de la Fuente
Journal:  Epigenetics       Date:  2016-03-28       Impact factor: 4.528

7.  Distinct host species correlate with Anaplasma phagocytophilum ankA gene clusters.

Authors:  Wiebke Scharf; Sonja Schauer; Felix Freyburger; Miroslav Petrovec; Daniel Schaarschmidt-Kiener; Gabriele Liebisch; Martin Runge; Martin Ganter; Alexandra Kehl; J Stephen Dumler; Ana L Garcia-Perez; Jennifer Jensen; Volker Fingerle; Marina L Meli; Armin Ensser; Snorre Stuen; Friederike D von Loewenich
Journal:  J Clin Microbiol       Date:  2010-12-22       Impact factor: 5.948

8.  ADAM10 and Notch1 on murine dendritic cells control the development of type 2 immunity and IgE production.

Authors:  S R Damle; R K Martin; C L Cockburn; J C Lownik; J A Carlyon; A D Smith; D H Conrad
Journal:  Allergy       Date:  2017-08-31       Impact factor: 13.146

Review 9.  Bacterial Type IV secretion systems: versatile virulence machines.

Authors:  Daniel E Voth; Laura J Broederdorf; Joseph G Graham
Journal:  Future Microbiol       Date:  2012-02       Impact factor: 3.165

10.  Ehrlichia chaffeensis tandem repeat proteins and Ank200 are type 1 secretion system substrates related to the repeats-in-toxin exoprotein family.

Authors:  Abdul Wakeel; Amke den Dulk-Ras; Paul J J Hooykaas; Jere W McBride
Journal:  Front Cell Infect Microbiol       Date:  2011-12-30       Impact factor: 5.293

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.